Results 61 to 70 of about 57,759 (194)

DNA Triplex-Formation by a Covalent Conjugate of the Anticancer Drug Temozolomide

open access: yesDNA
Background/Objectives: Temozolomide is an important drug used for the treatment of glioblastoma multiforme. Covalent conjugation of temozolomide to triplex-forming oligonucleotides could facilitate better sequence discrimination when targeted to DNA to ...
Andrew J. Walsh, William Fraser
doaj   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

open access: yesCase Reports in Oncology, 2013
Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy.
Laura Van Ginderachter   +7 more
doaj   +1 more source

Conditional survival in glioblastoma: The evolution of prognostic factors over time

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Neurooncologists rely on glioblastoma risk stratification systems for incorporating known disease‐ and patient‐specific factors at diagnosis. Although useful for general comparison and disease monitoring, these estimates are less informative for patients who survive beyond various time intervals post‐diagnosis.
Timothy Mueller   +19 more
wiley   +1 more source

Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

open access: yesiScience
Summary: Resistance to chemotherapies such as temozolomide is a major hurdle to effectively treat therapy-resistant glioblastoma. This challenge arises from the activation of phosphatidylinositol 3-kinase (PI3K), which makes it an appealing therapeutic ...
Kevin J. Pridham   +12 more
doaj   +1 more source

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients

open access: yesAnnals of Saudi Medicine, 2012
BACKGROUND AND OBJECTIVES: Currently, radiotherapy with concomitant and adjuvant temozolomide has become the standard treatment for glioblastoma. The purpose of this study was to report our experience with radiation plus concomitant temozolomide in 116 ...
Nilgun Ozbek Okumus   +5 more
doaj   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken   +20 more
wiley   +1 more source

Progress of temozolomide in the treatment of recurrent high-grade gliomas

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2013
High-grade gliomas are central nervous system malignancies which are difficult to treat. Surgery, temozolomide combined with radiotherapy postoperatively and adjuvant chemotherapy with temozolomide have been established as the standard treatment options ...
Jin-duo LI   +7 more
doaj  

In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide

open access: yesGlioma, 2018
Background: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Current treatment against this tumor consists of maximal surgical resection without threatening the patient's life, followed by a treatment with temozolomide, with or ...
Javier de la Rosa   +5 more
doaj   +1 more source

RTA‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the
Hung‐Pei Tsai   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy